A Phase 2 interventional study of NE3107 and Placebo in Parkinsons Disease (PD), sponsored by BioVie Inc.. Completed at 4 sites in United States. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by BioVie Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,649 studies in Parkinson Disease with a site in United States — 304 open to participants now, 386 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,649 studies in Parkinson Disease with a site in United States, this one is the 453rd largest by enrollment of the 1,256 interventional ones that give a count, is one of 78 that started in 2025, is one of 234 in phase 2, and was the 1,493rd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →304 of the 1,649 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, Ireland and 2 more countries
Ages 40–85
Medical University of South Carolina · Sites in United States
Ages 50–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 45 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,649 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 78 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,256 interventional studies, 78 across the 379 observational. Of the 1,140 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,649 have an industry lead sponsor. The 10 most frequent:
BioVie Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
BioVie Inc. has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
138 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT05558189Stanford UniversityVibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients | 2026-11-21 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
Add all 138 to your calendar (.ics) → With an account.
Among the 1,649 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are:
Researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of Parkinson's disease.
Participants will
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive 20 mg NE3107 BID (twice daily administration; 40 mg daily) as oral capsules.
Drug: NE3107
Subjects will receive matching placebo capsules for oral administration BID (twice daily).
Drug: Placebo
NE3107 20 mg BID
Also known as: bezisterim
Placebo BID
Monocyte Lymphocyte Ratio (MLR)
A unitless inflammatory biomarker calculated by dividing the absolute peripheral blood monocyte count by the absolute peripheral blood lymphocyte count, using values derived from clinical hematology (complete blood count with differential)
Time frame: 12 Weeks
Change in Systemic Inflammation Response Index (SIRI)
A unitless measure of systemic inflammation calculated as the product of the absolute blood neutrophil count and absolute blood monocyte count divided by the absolute blood lymphocyte count in samples obtained for clinical hematology testing.
Time frame: 12 weeks
Change in Neutrophil-to-Lymphocyte Ratio (NLR)
A unitless measure of systemic inflammation calculated as the ratio of the absolute peripheral blood neutrophil count to the absolute peripheral blood lymphocyte count obtained from routine clinical hematology assessments.
Time frame: 12 weeks
Change in Systemic Immune-Inflammation Index (SII)
A unitless composite measure of systemic inflammation and immune status calculated as the product of the absolute peripheral blood platelet count and neutrophil count divided by the absolute peripheral blood lymphocyte count obtained from routine clinical hematology assessments.
Time frame: 12 weeks
Change in Platelet-to-Lymphocyte Ratio (PLR)
A unitless measure of systemic inflammation calculated as the ratio of the absolute peripheral blood platelet count to the absolute peripheral blood lymphocyte count obtained from routine clinical hematology assessments.
Time frame: 12 weeks
Change in Aggregate Index of Systemic Inflammation (AISI)
A unitless composite measure of systemic inflammation calculated as the product of the absolute peripheral blood neutrophil count, monocyte count, and platelet count divided by the absolute peripheral blood lymphocyte count obtained from routine clinical hematology assessments.
Time frame: 12 weeks
Change in the Composite Benefit Score (CBS)
Early Parkinson's Neuro-Inflammatory Composite-15 (EPNIC-15), a composite endpoint consisting of 15 clinically relevant motor and non-motor measures derived from MDS-UPDRS Parts I, II, and III and PDSS-2 assessments. Lower scores indicate improvement in Parkinson's disease symptoms.
Time frame: 12 weeks
Change in MDS-UPDRS modified Part III
Change from baseline in MDS-UPDRS Modified Part III score, a clinician-rated measure of Parkinson's disease motor signs assessed using a modified Part III examination. The scale evaluates motor manifestations including speech, tremor, rigidity, bradykinesia, gait, posture, and postural stability. Higher scores indicate worse motor impairment.
Time frame: 12 weeks
Change in MDS-UPDRS Part II scores
Change from baseline in MDS-UPDRS Part II score. MDS-UPDRS Part II assesses the impact of Parkinson's disease motor symptoms on activities of daily living, with higher scores indicating greater impairment and negative changes indicating improvement.
Time frame: 12 weeks
Change in MDS-UPDRS Part I scores
Change from baseline in MDS-UPDRS Part I score. MDS-UPDRS Part I assesses non-motor experiences of daily living in Parkinson's disease, with higher scores indicating greater symptom burden and negative changes indicating improvement.
Time frame: 12 weeks
Change in MDS-UPDRS combined scores
Change from baseline in the combined MDS-UPDRS score (Parts I + II + III). The combined score assesses overall Parkinson's disease burden across non-motor symptoms, activities of daily living, and motor signs, with higher scores indicating greater impairment and negative changes indicating improvement.
Time frame: 12 weeks
Change in PDQ-39 score
Change from baseline in PDQ-39 total score. The Parkinson's Disease Questionnaire-39 (PDQ-39) assesses health-related quality of life across eight domains affected by Parkinson's disease. Higher scores indicate worse quality of life and negative changes indicate improvement.
Time frame: 12 weeks
Clinician's General Impression of Improvement (CGI-I)
Clinician's Global Impression of Improvement (CGI-I) score. The CGI-I is a clinician-rated measure of overall change in a participant's condition compared with baseline, scored on a 7-point scale from 1 (very much improved) to 7 (very much worse). Lower scores indicate greater improvement.
Time frame: 12 weeks
Clinician's General Impression of Severity (CGI-S)
Change from baseline in Clinician's Global Impression of Severity (CGI-S) score. The CGI-S is a clinician-rated measure of overall illness severity scored on a 7-point scale from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate greater severity and negative changes indicate improvement.
Time frame: 12 weeks
Change in PARCOMS-Motor (modified to adjust for missing MDS-UPDRS Part III scores)
Change from baseline in modified PARCOMS-Motor score. PARCOMS-Motor is a composite measure of Parkinson's disease motor symptoms derived from MDS-UPDRS motor assessments. The score was modified to adjust for missing MDS-UPDRS Part III data. Higher scores indicate greater motor impairment and negative changes indicate improvement
Time frame: 12 weeks
Change in PDSS-2
Change from baseline in PDSS-2 total score. The Parkinson's Disease Sleep Scale-2 (PDSS-2) assesses sleep disturbances and nocturnal symptoms associated with Parkinson's disease. Higher scores indicate worse sleep impairment and negative changes indicate improvement.
Time frame: 12 weeks
Change in DNA methylation
Change from baseline in DNA methylation levels measured in peripheral blood samples. DNA methylation is an epigenetic biomarker associated with regulation of gene expression and cellular function.
Time frame: 12 weeks
Percent change in hematologic inflammatory biomarker indices
Percent change from baseline in hematologic inflammatory biomarker indices (MLR, NLR, PLR, SIRI, SII, and AISI) derived from routine hematology testing. These indices are calculated from peripheral blood cell counts and are used as measures of systemic inflammation.
Time frame: 12 weeks
Change in plasma biomarkers of inflammation
Change from baseline in plasma biomarkers of inflammation measured in peripheral blood samples. Plasma inflammatory biomarkers are indicators of immune and inflammatory activity that may reflect biological responses to treatment.
Time frame: 12 week
Interaction between baseline inflammation level and treatment effect on changes in circulating inflammatory indices
Interaction between baseline inflammation level and treatment effect on changes in circulating inflammatory indices. Analysis of whether treatment effects on MLR, NLR, PLR, SIRI, SII, and AISI vary according to baseline systemic inflammation status.
Time frame: 12 weeks
Interaction between baseline inflammation level and treatment effect on changes in clinical endpoints
Interaction between baseline inflammation level and treatment effect on changes in clinical endpoints. Analysis of whether treatment effects on clinical measures vary according to baseline systemic inflammation status.
Time frame: 12 weeks
Interaction between change in inflammation level and treatment effect on changes in circulating inflammatory indices
Relationship between change in inflammation level and change from baseline in circulating inflammatory indices (MLR, NLR, PLR, SIRI, SII, and AISI). Analysis of whether treatment-related changes in systemic inflammation are associated with changes in circulating inflammatory biomarkers.
Time frame: 12 week
Interaction between change in inflammation level and treatment effect on changes in clinical endpoints
Relationship between change in inflammation level and change from baseline in clinical endpoints. Analysis of whether treatment-related changes in systemic inflammation are associated with changes in clinical measures of Parkinson's disease.
Time frame: 12 weeks
Percent of subjects with any improvement from baseline as measured by CGI-I
Percent of participants with improvement on CGI-I. Improvement is defined as a CGI-I score of 1 (very much improved), 2 (much improved), or 3 (minimally improved). The CGI-I is a clinician-rated measure of overall change from baseline
Time frame: 12 weeks
Percent of subjects with any improvement from baseline as measured by CGI-S
Percent of participants with improvement in CGI-S score from baseline. Improvement is defined as any decrease from baseline in the Clinician's Global Impression of Severity (CGI-S) score. The CGI-S is a clinician-rated measure of overall illness severity scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Lower scores indicate less severe illness.
Time frame: 12 weeks
Biological and disease phenotype subgroup analyses for changes in circulating inflammatory biomarker indices
Biological and disease phenotype subgroup analyses of changes in circulating inflammatory biomarker indices (MLR, NLR, PLR, SIRI, SII, and AISI). Analyses will evaluate whether treatment-related changes in inflammatory biomarkers differ across predefined biological and disease phenotype subgroups.
Time frame: 12 weeks
Biological and disease phenotype subgroup for changes in clinical endpoints
Biological and disease phenotype subgroup analyses of changes in clinical endpoints. Analyses will evaluate whether treatment-related changes in clinical outcome measures differ across predefined biological and disease phenotype subgroups.
Time frame: 12 weeks
Plan to share: No
Ran from Mar 2025 to primary completion in May 2026, 13 months.
Of 96 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 13 months is below that.
Counting every sponsor, half of 201 studies reached it within 28 months; a quarter within 16 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bezisterim
BioVie Inc.